Effect of melatonin receptor agonist on hypertension/endocrine disorders

Effect of melatonin receptor agonist on hypertension/endocrine disorders - Ramelteon-HTN/Endo study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009509

Enrollment

Registered

2012-12-10

Start date

2012-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension, metabolic syndrome

Interventions

treatment with ramelteon not treated with ramelteon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with insomnia but without sleep apnea syndrome patients with hypertension and/or obesity-related diseases

Exclusion criteria

Exclusion criteria: patients with contraindication for sleep medicine

Design outcomes

Primary

Measure	Time frame
blood pressure after treatment with ramelteon	—

Countries

Japan

Contacts

Public ContactKoichi Fukunaga

Keio university school of medicine internal medicine (respiratory)

k-fuku@jf7.so-net.ne.jp03-5363-3793

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026